ThermoGenesis Holdings Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de ThermoGenesis Holdings.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Apr 17

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Dec 15

ThermoGenesis EPS misses by $0.27, misses on revenue

Nov 12

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como ThermoGenesis Holdings no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

OTCPK:THMO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2024	10	-15	-5	-4	N/A
12/31/2023	9	-18	-5	-4	N/A
9/30/2023	10	-14	-4	-3	N/A
6/30/2023	10	-14	-5	-4	N/A
3/31/2023	10	-14	-5	-4	N/A
12/31/2022	10	-11	-8	-7	N/A
9/30/2022	10	-10	-7	-6	N/A
6/30/2022	11	-9	-7	-6	N/A
3/31/2022	10	-11	-7	-7	N/A
12/31/2021	9	-11	-7	-7	N/A
9/30/2021	9	-12	-9	-9	N/A
6/30/2021	8	-12	-11	-11	N/A
3/31/2021	8	-14	-16	-16	N/A
12/31/2020	10	-16	-14	-14	N/A
9/30/2020	10	-18	-12	-12	N/A
6/30/2020	11	-17	-9	-9	N/A
3/31/2020	13	-12	-4	-3	N/A
12/31/2019	13	-9	-3	-3	N/A
9/30/2019	14	-13	-4	-3	N/A
6/30/2019	13	-13	-4	-4	N/A
3/31/2019	11	-39	-8	-7	N/A
12/31/2018	10	-40	-8	-7	N/A
9/30/2018	10	-32	-10	-9	N/A
6/30/2018	10	-32	-11	-9	N/A
3/31/2018	11	-6	-8	-7	N/A
12/31/2017	13	-6	N/A	-8	N/A
9/30/2017	14	-9	N/A	-7	N/A
6/30/2017	15	-29	N/A	-7	N/A
3/31/2017	14	-32	N/A	-6	N/A
12/31/2016	14	-40	N/A	-8	N/A
9/30/2016	13	-38	N/A	-10	N/A
6/30/2016	12	-19	N/A	-10	N/A
3/31/2016	13	-17	N/A	-10	N/A
12/31/2015	14	-11	N/A	-9	N/A
9/30/2015	15	-15	N/A	-8	N/A
6/30/2015	16	-15	N/A	-11	N/A
3/31/2015	16	-15	N/A	-11	N/A
12/31/2014	16	-12	N/A	-9	N/A
9/30/2014	16	-10	N/A	-10	N/A
6/30/2014	16	-9	N/A	-8	N/A
3/31/2014	16	-8	N/A	-7	N/A
12/31/2013	17	-7	N/A	-5	N/A
9/30/2013	17	-6	N/A	-4	N/A
6/30/2013	18	-3	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de THMO es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de THMO crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de THMO crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de THMO crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de THMO crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de THMO se prevé que sea elevada dentro de 3 años.

ThermoGenesis Holdings Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 25%

Forecast breakeven date moved forward to 2023

Price target decreased to US$1.00

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2022

Price target decreased to US$6.00

Recent updates

ThermoGenesis Holdings Receives Notice from Nasdaq Due to Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity for Continued Listing Under Nasdaq’s Listing Rule 5550(b)(1)

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

ThermoGenesis Holdings Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Listing Rule 5550(b)(1)

ThermoGenesis Holdings, Inc. announced delayed annual 10-K filing

New major risk - Share price stability

ThermoGenesis Holdings Receives Letter from The Nasdaq Stock Market Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

ThermoGenesis Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.288 million.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

ThermoGenesis Holdings, Inc. to Report Q3, 2023 Results on Nov 13, 2023

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 14, 2023

Consensus revenue estimates fall by 25%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q2, 2023 Results on Aug 10, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023

It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target decreased to US$1.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

ThermoGenesis Holdings, Inc. to Report Q1, 2023 Results on Nov 10, 2022

ThermoGenesis Holdings, Inc., Annual General Meeting, Dec 15, 2022

ThermoGenesis Holdings, Inc. has completed a Composite Units Offering in the amount of $2.0547 million.

Nasdaq Grants Extension to ThermoGenesis Holdings to Regain Compliance

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

ThermoGenesis reports Q2 results

ThermoGenesis Holdings, Inc. to Report Q4, 2022 Results on Aug 11, 2022

ThermoGenesis Holdings, Inc. Announces Board Changes

ThermoGenesis Holdings, Inc. Board Changes

ThermoGenesis Holdings, Inc. to Report Q1, 2022 Results on May 19, 2022

ThermoGenesis Holdings, Inc. announced delayed 10-Q filing

Forecast to breakeven in 2022

Price target decreased to US$6.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 3Q 2020)

Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?

Thermogenesis Awards Nih Sbir Phase I Grant to Develop Key Cell Processing Disposable for Quintessence Automated Manufacturing of Gene-Engineered Autologous Cell (Geac) Therapies

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$1.02 loss in 2Q 2020)

Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?

Consensus revenue estimates fall to US$9.94m

First quarter 2021 earnings released: US$0.21 loss per share (vs US$1.11 loss in 1Q 2020)

When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?

Consensus revenue estimates fall to US$13.6m

Full year 2020 earnings released: US$2.60 loss per share (vs US$3.36 loss in FY 2019)

ThermoGenesis Holdings, Inc. to Report Q4, 2020 Results on Mar 17, 2021

Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt

New 90-day high: US$3.85

Thermogenesis Holdings, Inc. Launches A Gmp Compliant Automated Cell Washing and Reformulation System -- Pxp™-Lavare -- for Car-T Manufacturing

New 90-day high: US$2.73

New 90-day low: US$2.10

Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?

Earnings beat expectations, revenue disappoints

Third quarter 2020 earnings released: US$0.37 loss per share

ThermoGenesis EPS misses by $0.27, misses on revenue

ThermoGenesis Holdings, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: US$2.55

New 90-day low: US$3.24

New 90-day low - US$3.66

First half earnings released

ThermoGenesis Holdings, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura